InVivoMAb anti-mouse MHC Class I (H-2Kd)

Catalog #BE0104
Product Citations:
4
Clone:
SF1.1.10 (HB-159)
Reactivities:
Mouse

$164.00 - $4,280.00

Choose an Option...
  • 100 mg - $4,280.00
  • 50 mg - $3,024.00
  • 25 mg - $2,009.00
  • 5 mg - $600.00
  • 1 mg - $164.00
  • Custom Amount (Quotes Only)
In stock
Only %1 left

Product Details

The SF1.1.10 monoclonal antibody reacts with the mouse H-2Kd MHC class I alloantigen. MHC class I antigens are heterodimers consisting of one alpha chain (44 kDa) associated with Ɵ2 microglobulin (11.5 kDa). The antigen is expressed by all nucleated cells at varying levels. MHC Class I molecules present endogenously synthesized antigenic peptides to CD8 T cells.

Specifications

Isotype Mouse IgG2a, Īŗ
Recommended Isotype Control(s) InVivoMAb mouse IgG2a isotype control, unknown specificity
Recommended Dilution Buffer InVivoPure pH 7.0 Dilution Buffer
Conjugation This product is unconjugated. Conjugation is available via our Antibody Conjugation Services.
Immunogen BALB/c mouse spleen cells
Reported Applications Purification of MHC peptide complexes
in vivo administration
Flow cytometry
Formulation PBS, pH 7.0
Contains no stabilizers or preservatives
Endotoxin <2EU/mg (<0.002EU/Ī¼g)
Determined by LAL gel clotting assay
Purity >95%
Determined by SDS-PAGE
Sterility 0.2 Āµm filtration
Production Purified from cell culture supernatant in an animal-free facility
Purification Protein A
RRID AB_10948997
Molecular Weight 150 kDa
Storage The antibody solution should be stored at the stock concentration at 4Ā°C. Do not freeze.
Purification of MHC peptide complexes
Vormehr, M., et al. (2019). "A non-functional neoepitope specific CD8(+) T-cell response induced by tumor derived antigen exposure in vivo" Oncoimmunology 8(3): 1553478. PubMed

neoepitopes and prime targets for effective anti-cancer T-cell immunity. T cells recognizing cancer mutations are critical for the clinical activity of immune checkpoint blockade (ICB) and they are potent vaccine antigens. High frequencies of mutation-specific T cells are rarely spontaneously induced. Hence, therapies that broaden the tumor specific T-cell response are of interest. Here, we analyzed neoepitope-specific CD8(+) T-cell responses mounted either spontaneously or after immunotherapy regimens, which induce local tumor inflammation and cell death, in mice bearing tumors of the widely used colon carcinoma cell line CT26. A comprehensive immune reactivity screening of 2474 peptides covering 628 transcribed CT26 point mutations was conducted. All tested treatment regimens were found to induce a single significant CD8(+) T-cell response against a non-synonymous D733A point mutation in the Smc3 gene. Surprisingly, even though Smc3 D733A turned out to be the immune-dominant neoepitope in CT26 tumor bearing mice, neither T cells specific for this neoepitope nor their T cell receptors (TCRs) were able to recognize or lyse tumor cells. Moreover, vaccination with the D733A neoepitope did not result in anti-tumoral activity despite induction of specific T cells. This is to our knowledge the first report that neoepitope specific CD8(+) T cells primed by tumor-released antigen exposure in vivo can be functionally irrelevant.

Flow Cytometry
Li, T., et al. (2018). "Transfer of multiple loci of donorā€™s genes to induce recipient tolerance in organ transplantation" Exp Ther Med 15(6): 4961-4971. PubMed

Donor organ rejection remains a significant problem. The present study aimed to assess whether transferring a donorā€™s major histocompatibility complex (MHC) genes to the recipient could mitigate rejection in organ transplantation. Seven loci of MHC genes from donor mice were amplified and ligated into vectors; the vectors either contained one K locus, seven loci or were empty (control). The vectors were subsequently injected into the thymus of recipients (in heterotransplants, recipient rats received the vector containing one K locus), following which donor mouse hearts were transplanted. Following the transplantation of allograft and heterograft, electrocardiosignals were viable for a significantly longer duration in recipient mice and rats receiving the donor histocompatibility-2 complex (H-2)(d) genes compared with those in controls, and in mice that received seven vectors compared with those receiving one vector. Mixed lymphocyte cultures containing cells from these recipients proliferated significantly less compared with mixed lymphocyte cultures containing controls. Also, hearts from H-2(d) genes-treated recipients demonstrated less lymphocyte infiltration and necrosis compared with the control recipient. The present study concluded that allograft and heterograft rejection may be mitigated by introducing the donorā€™s MHC into the recipient; transferring seven loci has been demonstrated to be more effective than transferring one locus.

Purification of MHC peptide complexes
Trujillo, J. A., et al. (2014). "The cellular redox environment alters antigen presentation" J Biol Chem 289(40): 27979-27991. PubMed

Cysteine-containing peptides represent an important class of T cell epitopes, yet their prevalence remains underestimated. We have established and interrogated a database of around 70,000 naturally processed MHC-bound peptides and demonstrate that cysteine-containing peptides are presented on the surface of cells in an MHC allomorph-dependent manner and comprise on average 5-10% of the immunopeptidome. A significant proportion of these peptides are oxidatively modified, most commonly through covalent linkage with the antioxidant glutathione. Unlike some of the previously reported cysteine-based modifications, this represents a true physiological alteration of cysteine residues. Furthermore, our results suggest that alterations in the cellular redox state induced by viral infection are communicated to the immune system through the presentation of S-glutathionylated viral peptides, resulting in altered T cell recognition. Our data provide a structural basis for how the glutathione modification alters recognition by virus-specific T cells. Collectively, these results suggest that oxidative stress represents a mechanism for modulating the virus-specific T cell response.

Flow Cytometry
Dudek, N. L., et al. (2012). "Constitutive and inflammatory immunopeptidome of pancreatic beta-cells" Diabetes 61(11): 3018-3025. PubMed

2,000 MHC-bound peptides; 1,100 of these presented by beta-cells grown under normal conditions or after exposure to IFN-gamma. These include sequences from a number of known autoantigens. Quantitation of IGRP(2)(0)(6)(-)(2)(1)(4) revealed low-level presentation by K(d) (~25 complexes/cell) on NIT-1 cells after IFN-gamma treatment compared with the simultaneous presentation of the endogenously processed K(d)-restricted peptide Janus kinase-1(3)(5)(5)(-)(3)(6)(3) (~15,000 copies/cell). We have successfully sequenced peptides from NIT-1 beta-cells under basal and inflammatory conditions. We have shown the feasibility of quantitating disease-associated peptides and provide the first direct demonstration of the disparity between presentation of a known autoantigenic epitope and a common endogenously presented peptide.ā€}ā€ data-sheets-userformat=ā€{ā€œ2ā€³:14851,ā€3ā€:{ā€œ1ā€³:0},ā€4ā€:{ā€œ1ā€³:2,ā€2ā€³:16777215},ā€12ā€³:0,ā€14ā€:{ā€œ1ā€³:2,ā€2ā€³:1521491},ā€15ā€³:ā€Roboto, sans-serifā€,ā€16ā€³:12}ā€>Type 1 diabetes is characterized by the autoimmune destruction of pancreatic beta-cells. Recognition of major histocompatibility complex (MHC)-bound peptides is critical for both the initiation and progression of disease. In this study, MHC peptide complexes were purified from NIT-1 beta-cells, interferon-gamma (IFN-gamma)-treated NIT-1 cells, splenic and thymic tissue of 12-week-old NOD mice, and peptides identified by mass spectrometry. In addition to global liquid chromatography-tandem mass spectrometry analysis, the targeted approach of multiple-reaction monitoring was used to quantitate the immunodominant K(d)-restricted T-cell epitope islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP)(2)(0)(6)(-)(2)(1)(4). We identified >2,000 MHC-bound peptides; 1,100 of these presented by beta-cells grown under normal conditions or after exposure to IFN-gamma. These include sequences from a number of known autoantigens. Quantitation of IGRP(2)(0)(6)(-)(2)(1)(4) revealed low-level presentation by K(d) (~25 complexes/cell) on NIT-1 cells after IFN-gamma treatment compared with the simultaneous presentation of the endogenously processed K(d)-restricted peptide Janus kinase-1(3)(5)(5)(-)(3)(6)(3) (~15,000 copies/cell). We have successfully sequenced peptides from NIT-1 beta-cells under basal and inflammatory conditions. We have shown the feasibility of quantitating disease-associated peptides and provide the first direct demonstration of the disparity between presentation of a known autoantigenic epitope and a common endogenously presented peptide.

in vivo administration
Jindra, P. T., et al. (2008). "Anti-MHC class I antibody activation of proliferation and survival signaling in murine cardiac allografts" J Immunol 180(4): 2214-2224. PubMed

Anti-MHC class I alloantibodies have been implicated in the process of acute and chronic rejection because these Abs can bind to endothelial cells and transduce signals leading to the activation of cell survival and proliferation pathways. To characterize the role of the MHC class I-signaling pathway in the pathogenesis of Ab-mediated rejection, we developed a mouse vascularized heterotopic cardiac allograft model in which B6.RAG1 KO hosts (H-2K(b)/D(b)) received a fully MHC-incompatible BALB/c (H-2K(d)/D(d)) heart transplant and were passively transfused with anti-donor MHC class I Ab. We demonstrate that cardiac allografts of mice treated with anti-MHC class I Abs show characteristic features of Ab-mediated rejection including microvascular changes accompanied by C4d deposition. Phosphoproteomic analysis of signaling molecules involved in the MHC class I cell proliferation and survival pathways were elevated in anti-class I-treated mice compared with the isotype control-treated group. Pairwise correlations, hierarchical clustering, and multidimensional scaling algorithms were used to dissect the class I-signaling pathway in vivo. Treatment with anti-H-2K(d) Ab was highly correlated with the activation of Akt and p70S6Kinase (S6K). When measuring distance as a marker of interrelatedness, multidimensional scaling analysis revealed a close association between members of the mammalian target of rapamycin pathway including mammalian target of rapamycin, S6K, and S6 ribosomal protein. These results provide the first analysis of the interrelationships between these signaling molecules in vivo that reflects our knowledge of the signaling pathway derived from in vitro experiments.

Flow Cytometry
Guerrero-Plata, A., et al. (2004). "Antigen presentation by a macrophage-like cell line persistently infected with respiratory syncytial virus" Virus Res 99(1): 95-100. PubMed

Severe infection by the human respiratory syncytial virus (RSV) early in life is associated with subsequent recurrent airway disease presumably mediated by dysregulation of the local immune response. Dysfunction of the immune response may be related to impaired macrophage functions. We have previously reported that RSV persistence in a macrophage culture (MPhiper) alters Fcgamma receptors (FcgammaR)-mediated phagocytosis and the production of pro-inflammatory cytokines. Here, we determined whether the ability of macrophages to process and present antigens and to stimulate RSV-specific CD8(+) T cells was altered in MPhiper. We also examined the level of expression of MHC class I molecules in MPhiper and the ability of these cells to present viral antigens to specific T lymphocytes. Our results showed that antigen processing and presentation were not altered by chronic RSV infection, and suggested that MPhiper were able to stimulate RSV-specific CD8(+) T lymphocytes.

Flow Cytometry
Diaz-Quinonez, A., et al. (2004). "Two Salmonella OmpC K(b)-restricted epitopes for CD8+-T-cell recognition" Infect Immun 72(5): 3059-3062. PubMed

We report the identification of two peptides from Salmonella OmpC porin that can bind to major histocompatibility complex class I K(b) molecules and are targets of cytotoxic T lymphocytes from Salmonella-infected mice. These peptides are conserved in gram-negative bacterial porins and are the first Salmonella porin-specific epitopes described for possible CD8(+)-T-cell elimination of infected cells.

    • Mus musculus (House mouse)
    • ,
    Immunopeptidome mining reveals a novel ERS-induced target in T1D

    Preprint on Research Square on 9 June 2023 by Wang, L., Li, J., et al.

    PubMed

    Autoreactive CD8 + T cells play a key role in type 1 diabetes (T1D), but the antigen spectrum that activates autoreactive CD8 + T cells remains unclear. Endoplasmic reticulum stress (ERS) has been implicated in Ī² cell autoantigen generation. Here, we analyzed the major histocompatibility complex class I (MHC-I)-associated immunopeptidome (MIP) of islet Ī² cells under steady-state and ERS conditions and found a small number of peptides that were exclusively present in the MIP of the ERS-exposed Ī² cell line. Among them, OTUB2 58ā€‰āˆ’ā€‰66 showed immunodominance, and the corresponding autoreactive CD8 + T cells were diabetogenic in NOD mice. High glucose intake upregulated pancreatic OTUB2 expression and amplified the OTUB2 58ā€‰āˆ’ā€‰66 -specific CD8 + T-cell response in NOD mice. Repeated OTUB2 58ā€‰āˆ’ā€‰66 administration significantly reduced the T1D incidence in these mice. This study provides novel Ī² cell autoantigens for developing specific immune interventions for T1D prevention and treatment. Data are available via ProteomeXchange with identifier PXD041227.

    • Endocrinology and Physiology
    • ,
    • Immunology and Microbiology
    Anti-donor MHC Class II Alloantibody Induces Glomerular Injury in Mouse Renal Allografts Subjected to Prolonged Cold Ischemia.

    In Journal of the American Society of Nephrology : JASN on 1 December 2019 by Gorbacheva, V., Fan, R., et al.

    PubMed

    The mechanisms underlying the effects of prolonged cold-ischemia storage on kidney allografts are poorly understood. To investigate effects of cold ischemia on donor-reactive immune responses and graft pathology, we used a mouse kidney transplantation model that subjected MHC-mismatched BALB/c kidney allografts to cold-ischemia storage for 0.5 or 6 hours before transplant into C57BL/6 mice. At day 14 post-transplant, recipients of allografts subjected to 6 versus 0.5 hours of cold-ischemia storage had increased levels of anti-MHC class II (but not class I) donor-specific antibodies, increased donor-reactive T cells, and a significantly higher proportion of transplant glomeruli infiltrated with macrophages. By day 60 post-transplant, allografts with a 6 hour cold-ischemia time developed extensive glomerular injury compared with moderate pathology in allografts with 0.5 hour of cold-ischemia time. Pathology was associated with increased serum levels of anti-class 2 but not anti-class 1 donor-specific antibodies. Recipient B cell depletion abrogated early macrophage recruitment, suggesting augmented donor-specific antibodies, rather than T cells, increase glomerular pathology after prolonged cold ischemia. Lymphocyte sequestration with sphingosine-1-phosphate receptor 1 antagonist FTY720 specifically inhibited anti-MHC class II antibody production and abrogated macrophage infiltration into glomeruli. Adoptive transfer of sera containing anti-donor MHC class II antibodies or mAbs against donor MHC class II restored early glomerular macrophage infiltration in FTY720-treated recipients. Post-transplant inflammation augments generation of donor-specific antibodies against MHC class II antigens. Resulting MHC class II-reactive donor-specific antibodies are essential mediators of kidney allograft glomerular injury caused by prolonged cold ischemia. Copyright Ā© 2019 by the American Society of Nephrology.

    • Immu-puri
    • ,
    • Homo sapiens (Human)
    • ,
    • Cancer Research
    • ,
    • Immunology and Microbiology
    A non-functional neoepitope specific CD8+ T-cell response induced by tumor derived antigen exposure in vivo.

    In Oncoimmunology on 7 February 2019 by Vormehr, M., Reinhard, K., et al.

    PubMed

    Cancer-associated mutations, mostly single nucleotide variations, can act as neoepitopes and prime targets for effective anti-cancer T-cell immunity. T cells recognizing cancer mutations are critical for the clinical activity of immune checkpoint blockade (ICB) and they are potent vaccine antigens. High frequencies of mutation-specific T cells are rarely spontaneously induced. Hence, therapies that broaden the tumor specific T-cell response are of interest. Here, we analyzed neoepitope-specific CD8+ T-cell responses mounted either spontaneously or after immunotherapy regimens, which induce local tumor inflammation and cell death, in mice bearing tumors of the widely used colon carcinoma cell line CT26. A comprehensive immune reactivity screening of 2474 peptides covering 628 transcribed CT26 point mutations was conducted. All tested treatment regimens were found to induce a single significant CD8+ T-cell response against a non-synonymous D733A point mutation in the Smc3 gene. Surprisingly, even though Smc3 D733A turned out to be the immune-dominant neoepitope in CT26 tumor bearing mice, neither T cells specific for this neoepitope nor their T cell receptors (TCRs) were able to recognize or lyse tumor cells. Moreover, vaccination with the D733A neoepitope did not result in anti-tumoral activity despite induction of specific T cells. This is to our knowledge the first report that neoepitope specific CD8+ T cells primed by tumor-released antigen exposure in vivo can be functionally irrelevant.

    • FC/FACS
    • ,
    • Mus musculus (House mouse)
    Transfer of multiple loci of donor's genes to induce recipient tolerance in organ transplantation.

    In Experimental and Therapeutic Medicine on 1 June 2018 by Li, T., Zhang, W., et al.

    PubMed

    Donor organ rejection remains a significant problem. The present study aimed to assess whether transferring a donor's major histocompatibility complex (MHC) genes to the recipient could mitigate rejection in organ transplantation. Seven loci of MHC genes from donor mice were amplified and ligated into vectors; the vectors either contained one K locus, seven loci or were empty (control). The vectors were subsequently injected into the thymus of recipients (in heterotransplants, recipient rats received the vector containing one K locus), following which donor mouse hearts were transplanted. Following the transplantation of allograft and heterograft, electrocardiosignals were viable for a significantly longer duration in recipient mice and rats receiving the donor histocompatibility-2 complex (H-2)d genes compared with those in controls, and in mice that received seven vectors compared with those receiving one vector. Mixed lymphocyte cultures containing cells from these recipients proliferated significantly less compared with mixed lymphocyte cultures containing controls. Also, hearts from H-2d genes-treated recipients demonstrated less lymphocyte infiltration and necrosis compared with the control recipient. The present study concluded that allograft and heterograft rejection may be mitigated by introducing the donor's MHC into the recipient; transferring seven loci has been demonstrated to be more effective than transferring one locus.